Abstract
Adiponectin is an adipocyte hormone that ameliorates insulin resistance and prevents diabetes. Patients with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) are at a high risk of developing diabetes and cardiovascular diseases. Since treatment with angiotensin II receptor blockers retards the development of diabetes, the effects of losartan on serum adiponectin levels were examined with regard to insulin sensitivity in pre-diabetic patients. Sixty-five patients with IFG/IGT (42 males, 23 females, 63±13 years old) were randomized to receive 25–100 mg of losartan (n=33) or a calcium channel blocker (CCB, n=32) for 3 months. Before and after the treatment, changes in blood pressure, insulin sensitivity (HOMAR) and serum concentrations of high molecular weight (HMW)-adiponectin and free fatty acid (FFA) were assessed. At baseline, the HMW-adiponectin concentration negatively correlated with the patient's body mass index, HOMA-R and triglyceride levels, and positively correlated with high-density lipoprotein (HDL)- cholesterol levels. However, the HMW-adiponectin concentration showed no correlation with blood pressure. HMW-adiponectin concentrations were similar between the losartan group and the CCB group. Both the losartan and CCB treatments similarly and significantly reduced the mean blood pressure (107±7 mmHg to 95±7 mmHg, p<0.0001, and 104±6 mmHg to 93±9 mmHg, p<0.0001, respectively). Losartan treatment resulted in a significant increase in HMW-adiponectin concentrations (45.9%) and a significant decrease in HOMA-R (23.9%) and FFA concentrations (26.5%); the percent changes were greater than those induced by CCB treatment (p<0.001, p<0.05 and p<0.01, respectively). We conclude that losartan increases the serum HMW-adiponectin concentration and concurrently improves insulin sensitivity in subjects with IFG/IGT. These results suggest that losartan may prevent diabetes by increasing serum adiponectin levels.
Similar content being viewed by others
Article PDF
References
Donahue RP, Orchard TJ : Diabetes mellitus and macrovascular complications. An epidemiological perspective. Diabetes Care 1992; 15: 1141–1155.
Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ : Joslin's Diabetes Mellitus. Philadelphia, Lippincott Williams & Wilkins, 2004, 1224 pp.
von Eckardstein A, Schulte H, Assmann G : Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Münster. J Clin Endo-crinol Metab 2000; 85: 3101–3108.
Edelstein SL, Knowler WC, Bain RP, et al: Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997; 46: 701–710.
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF : A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746–26749.
Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K : cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286–289.
Hu E, Liang P, Spiegelman BM : AdipoQ is a novel adiposespecific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697–10703.
Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M : Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996; 120: 803–812.
Weyer C, Funahashi T, Tanaka S, et al: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930–1935.
Yamauchi T, Kamon J, Minokoshi Y, et al: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288–1295.
Daimon M, Oizumi T, Saitoh T, et al: Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 2003; 26: 2015–2020.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K : Adiponectin and adiponectin receptors in insulin 1618 Hypertens Res Vol. 31, No. 8 (2008) resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784–1792.
Yamauchi T, Kamon J, Waki H, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941–946.
Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Julius S, Kjeldsen SE, Weber M, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.
Shao J, Iwashita N, Ikeda F, et al: Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on betacell function and morphology in db/db mice. Biochem Biophys Res Commun 2006; 344: 1224–1233.
Furuhashi M, Ura N, Higashiura K, et al: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76–81.
Watanabe S, Okura T, Kurata M, et al: The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther 2006; 28: 1677–1685.
Waki H, Yamauchi T, Kamon J, et al: Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352–40363.
Kobayashi H, Ouchi N, Kihara S, et al: Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004; 94: e27–e31.
World Health Organization: Report of a WHO Consultation: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Part 1. Diagnosis and Classification of Diabetes Mellitus. Geneva, Department of Noncommunicable Disease Surveillance, World Health Organization, 1999.
Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypetens Res 2006; 29 ( Suppl): S1–S105.
Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35: S1–S140.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC : Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
Katz A, Nambi SS, Mather K, et al: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402–2410.
Taniguchi A, Fukushima M, Sakai M, et al: Insulin-sensitive and insulin-resistant variants in nonobese Japanese type 2 diabetic patients. The role of triglycerides in insulin resistance. Diabetes Care 1999; 22: 2100–2101.
Xu A, Chan KW, Hoo RL, et al: Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005; 280: 18073–18080.
Murakami H, Ura N, Furuhashi M, Higashiura K, Miura T, Shimamoto K : Role of adiponectin in insulin-resistant hypertension and atherosclerosis. Hypertens Res 2003; 26: 705–710.
Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA : Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 4649–4655.
Boden G, Chen X, Ruiz J, White JV, Rossetti L : Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994; 93: 2438–2446.
Katovich MJ, Pachori A : Effects of inhibition of the reninangiotensin system on the cardiovascular actions of insulin. Diabetes Obes Metab 2000; 2: 3–14.
Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J : Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care 1990; 13: 1109–1111.
Okada K, Hirano T, Ran J, Adachi M : Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructosefed rats. Hypertens Res 2004; 27: 293–299.
Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC : Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609–611.
Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993–1002.
Kurtz TW, Pravenec M : Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253–2261.
Schupp M, Lee LD, Frost N, et al: Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension 2006; 47: 586–589.
Picard F, Auwerx J : PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 2002; 22: 167–197.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nishimura, H., Sanaka, T., Tanihata, Y. et al. Losartan Elevates the Serum High-Molecular Weight—Adiponectin Isoform and Concurrently Improves Insulin Sensitivity in Patients with Impaired Glucose Metabolism. Hypertens Res 31, 1611–1618 (2008). https://doi.org/10.1291/hypres.31.1611
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1291/hypres.31.1611
Keywords
This article is cited by
-
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients
Hypertension Research (2011)
-
Comparison of the effects of losartan vs. ramipril on several adipocytokines and vascular remodeling biomarkers
Hypertension Research (2011)
-
Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model
Hypertension Research (2009)
